Pacific Heights Asset Management LLC Acquires New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR

Pacific Heights Asset Management LLC acquired a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 460,000 shares of the company’s stock, valued at approximately $9,540,000. Pacific Heights Asset Management LLC owned approximately 0.80% of Structure Therapeutics at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. National Bank of Canada FI raised its holdings in Structure Therapeutics by 1,448.2% in the first quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock worth $51,000 after purchasing an additional 2,766 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its holdings in Structure Therapeutics by 310.7% in the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock worth $74,000 after purchasing an additional 3,213 shares in the last quarter. Signaturefd LLC raised its holdings in Structure Therapeutics by 6,550.0% in the second quarter. Signaturefd LLC now owns 6,650 shares of the company’s stock worth $138,000 after purchasing an additional 6,550 shares in the last quarter. GAMMA Investing LLC raised its holdings in Structure Therapeutics by 663.8% in the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock worth $152,000 after purchasing an additional 7,627 shares in the last quarter. Finally, Parallel Advisors LLC bought a new position in Structure Therapeutics in the second quarter worth about $171,000. 91.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

GPCR has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. JMP Securities dropped their price target on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 7th. Lifesci Capital upgraded Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. HC Wainwright dropped their price target on Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Finally, Guggenheim dropped their price target on Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Structure Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $68.67.

Structure Therapeutics Stock Down 3.4%

Shares of NASDAQ GPCR opened at $26.92 on Wednesday. The business’s 50 day moving average price is $23.36 and its 200 day moving average price is $21.78. The firm has a market cap of $1.55 billion, a P/E ratio of -25.64 and a beta of -1.65. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $13.22 and a 52 week high of $42.57.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). As a group, research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.